sar441344
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 8, 2018 (NCT05845996)
Timeline
Indications
Mechanism of action
- CD40 ligandINHIBITOR
CD40LG inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05039840 | Phase 2 | Oct 31, 2021 | Sanofi |
| NCT04879628 | Phase 2 | Jun 7, 2021 | Sanofi |
| NCT04572841 | Phase 2 | Nov 12, 2020 | Sanofi |
| NCT05845996 | Phase 1 | Nov 8, 2018 | Sanofi |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 4 | 4 | 2 | 2018 |
1 organizations
Page 1 / 1